Published in Cancer J on September 19, 2001
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A (2009) 3.13
Pancreatic carcinogenesis. Pancreatology (2008) 2.60
Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest (2002) 2.28
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96
Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A (2010) 1.84
Precursors to pancreatic cancer. Gastroenterol Clin North Am (2007) 1.75
Genome-wide association study of pancreatic cancer in Japanese population. PLoS One (2010) 1.50
Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol (2004) 1.35
Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res (2009) 1.28
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci U S A (2011) 1.26
Mouse models of pancreatic cancer. World J Gastroenterol (2012) 1.20
Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. Cancer Biol Ther (2008) 1.10
HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Cancer Res (2014) 1.05
TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation. Cancer Res (2009) 1.02
Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction. BMC Biotechnol (2003) 1.02
Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg (2003) 1.01
CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis. PLoS One (2014) 0.99
The matricellular protein CCN1/Cyr61 is a critical regulator of Sonic Hedgehog in pancreatic carcinogenesis. J Biol Chem (2012) 0.98
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. Gastroenterology (2014) 0.93
Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells. Int J Cancer (2010) 0.93
GEMMs as preclinical models for testing pancreatic cancer therapies. Dis Model Mech (2015) 0.92
Ski promotes tumor growth through abrogation of transforming growth factor-beta signaling in pancreatic cancer. Ann Surg (2007) 0.90
Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions. Cell Rep (2016) 0.90
Emerging molecular biology of pancreatic cancer. Gastrointest Cancer Res (2008) 0.87
HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity. Oncotarget (2015) 0.86
SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells. BMC Cancer (2014) 0.86
Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression. Cell Rep (2014) 0.84
Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? Biomed Res Int (2016) 0.82
Pancreatic Cancer Cell Migration and Metastasis Is Regulated by Chemokine-Biased Agonism and Bioenergetic Signaling. Cancer Res (2015) 0.82
The molecular biology of pancreatic cancer. Gastrointest Cancer Res (2007) 0.81
Current approaches to novel therapeutics in pancreatic cancer. Invest New Drugs (2003) 0.81
Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation. World J Gastroenterol (2014) 0.80
The secret origins and surprising fates of pancreas tumors. Carcinogenesis (2014) 0.80
Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells. Genes Cancer (2014) 0.80
KRas, ROS and the initiation of pancreatic cancer. Small GTPases (2016) 0.78
The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer. Cancers (Basel) (2010) 0.78
Target discovery and validation in pancreatic cancer. Methods Mol Biol (2007) 0.77
Mitochondrial and Oxidative Stress-Mediated Activation of Protein Kinase D1 and Its Importance in Pancreatic Cancer. Front Oncol (2017) 0.75
Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions. EBioMedicine (2016) 0.75
The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship. Am J Surg Pathol (2016) 0.75
Molecular profiles of gastroenteropancreatic endocrine tumors. Virchows Arch (2007) 0.75
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol (2001) 6.30
Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell (1998) 5.88
Allelotype of colorectal carcinomas. Science (1989) 5.54
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Progression model for pancreatic cancer. Clin Cancer Res (2000) 4.60
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet (1996) 4.09
Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr (1997) 3.75
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res (2000) 3.74
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Scrambled exons. Cell (1991) 3.65
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell (1991) 3.59
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02
Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res (1998) 2.89
p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res (1997) 2.88
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res (1994) 2.80
The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev (1998) 2.72
Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol (2000) 2.63
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol (1999) 2.59
Genetic progression in the pancreatic ducts. Am J Pathol (2000) 2.58
Mad-related genes in the human. Nat Genet (1996) 2.51
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res (2001) 2.50
Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res (2000) 2.40
Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res (1994) 2.26
Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res (1998) 2.23
Allelotype of pancreatic adenocarcinoma. Cancer Res (1994) 2.11
Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. Am J Pathol (1997) 2.08
Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res (2001) 1.98
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res (1998) 1.97
Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res (2001) 1.96
STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol (2001) 1.89
Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol (2000) 1.81
Colorectal neoplasia in juvenile polyposis or juvenile polyps. Arch Dis Child (1991) 1.81
Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res (1996) 1.75
BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol (2000) 1.72
Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res (1998) 1.71
Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol (2000) 1.69
Remifentanil by bolus injection: a safety, pharmacokinetic, pharmacodynamic, and age effect investigation in human volunteers. Br J Anaesth (2004) 1.62
Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol (1996) 1.57
Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci U S A (1998) 1.55
A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res (2000) 1.53
Familial pancreatic cancer. Cancer J (2001) 1.51
Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res (2001) 1.49
Direct demonstration in intestinal secretions of an IgA memory response to orally administered Shigella flexneri antigens. J Immunol (1982) 1.46
Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol (1998) 1.42
Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen. Proc Natl Acad Sci U S A (1990) 1.39
Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev (1998) 1.36
K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol (1995) 1.35
Nomenclature: vertebrate mediators of TGFbeta family signals. Cell (1996) 1.34
Familial pancreatic cancer. Ann Oncol (1999) 1.33
Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res (1992) 1.31
Familial pancreatic cancer: a review. Semin Oncol (1996) 1.30
Dpc4 transcriptional activation and dysfunction in cancer cells. Cancer Res (1998) 1.29
ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci U S A (2001) 1.29
Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology (1995) 1.23
Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res (2001) 1.22
Progress in cancer genetics: lessons from pancreatic cancer. Ann Oncol (1999) 1.22
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer (2010) 1.21
Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells. Mol Carcinog (1999) 1.20
p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol (1995) 1.20
G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: phenotypes reversed by a tumorigenic mutation. Proc Natl Acad Sci U S A (1999) 1.19
Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer (1999) 1.19
Aberrant methylation of the Human Hedgehog interacting protein (HHIP) gene in pancreatic neoplasms. Cancer Biol Ther (2005) 1.18
Tumor-suppressor genes in pancreatic cancer. J Hepatobiliary Pancreat Surg (1998) 1.17
Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis. Kidney Int (2006) 1.17
Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer (2003) 1.16
Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res (1996) 1.14
Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol (2000) 1.13
Pathology of incipient pancreatic cancer. Ann Oncol (1999) 1.10